TARS
Tarsus Pharmaceuticals, Inc. Health Care Biological Products, (No Diagnostic Substances) Russell 3000
$74.85Close
$3.2BMarket cap
$56.11 – $90.7852-week range
Nov 3, 2026Next report
Highlights
Cautions
- Not in an uptrend 5 of 8 trend conditions
- Results soon Nov 3, 2026, in 2 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
18%
1wk
up 9.8%
price change
1mo
down 4.8%
price change
12-month return
up 9%
market up 11% ·
its own 0%
F-score
—
— Not assessed
Altman Z
8.89
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
9.3×
price / book
Earnings yield
down 2.3%
EBIT / enterprise value
Cheaper than
18%
of the market · expensive
Revenue growth
up 147%
year on year
EPS growth
—
latest quarter
Sales growth
up 69%
latest quarter · -37 pts
ROE
down 23%
return on equity
Free cash margin
down 5%
-$22.3M FCF
D/E
0.21
long-term debt / equity
Net debt / EBITDA
—
Interest cover
Lossoperating loss
Trade setup
ATR%
4.2%
$3.12 a day · 2×ATR $68.62
RS
74 / 99
vs the universe
Trend
5 / 8
150-day under the 200-day, 200-day not rising, under the 50-day
Relative volume
0.7×
vs 50-day average
Up/down volume
0.95
50 sessions
Implied move
—
no option chain · report Nov 3, 2026
Trend template · 5 of 8
- Price above the 150 and 200-day averages: passes
- 150-day average above the 200-day: fails
- 200-day average rising for a month: fails
- 50-day average above the 150 and 200-day: passes
- Price above the 50-day average: fails
- At least 30% above the 52-week low: passes
- Within 25% of the 52-week high: passes
- RS rank 70 or higher: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Losing money before interest is even paid The company made an operating loss, so interest is not covered at all - the debt is being serviced from cash reserves, asset sales or new borrowing rather than from the business.
- Shareholders diluted The share count rose 11.0% over the year, from 38m to 43m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 6, 2026
Results reaction
Aug 6, 2026+5% vs market2 sessions after results
Financials
- Net -15%
- Free cash -5%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $57.0M | $25.8M | $17.4M | $183.0M | $451.4M |
| Operating income | -$27.0M | -$12.2M | -$62.7M | -$143.2M | -$120.6M | -$71.0M |
| Net income | -$26.8M | -$13.8M | -$62.1M | -$136.0M | -$116.0M | -$66.0M |
| Net margin | — | -24% | -241% | -780% | -63% | -15% |
| Earnings per share | -$4.32 | -$0.67 | -$2.52 | -$4.63 | -$3.08 | -$1.58 |
| Free cash flow | -$21.6M | $3.2M | -$49.5M | -$119.0M | -$84.6M | -$22.3M |
| Free cash margin | — | 6% | -192% | -682% | -46% | -5% |
| Cash | $168.1M | $171.3M | $71.7M | $224.9M | $94.8M | $183.6M |
| Long-term debt | — | $0 | $19.4M | $29.8M | $71.8M | $72.4M |
| Shareholders' equity | $166.0M | $166.7M | $192.9M | $197.0M | $224.5M | $343.4M |
| Shares outstanding | 20.32m | 20.70m | 26.70m | 34.21m | 38.35m | 42.55m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 6, 2026 | Quarterly ↗ | Mar 31, 2026 | 36d |
| Feb 23, 2026 | Annual ↗ | Dec 31, 2025 | 54d |
| Nov 4, 2025 | Quarterly ↗ | Sep 30, 2025 | 35d |
| Aug 6, 2025 | Quarterly ↗ | Jun 30, 2025 | 37d |
| May 1, 2025 | Quarterly ↗ | Mar 31, 2025 | 31d |
| Feb 25, 2025 | Annual ↗ | Dec 31, 2024 | 56d |
| Nov 13, 2024 | Quarterly ↗ | Sep 30, 2024 | 44d |
| Aug 8, 2024 | Quarterly ↗ | Jun 30, 2024 | 39d |
| May 8, 2024 | Quarterly ↗ | Mar 31, 2024 | 38d |
| Feb 27, 2024 | Annual ↗ | Dec 31, 2023 | 58d |
| Nov 9, 2023 | Quarterly ↗ | Sep 30, 2023 | 40d |
Current reports
| Filed | Disclosed |
|---|---|
| Sep 10, 2026 | Acquisition or disposal · Other events ↗ |
| Aug 6, 2026 | Results ↗ |
| Aug 6, 2026 | Material agreement · Unregistered share sale · Other events ↗ |
| Aug 6, 2026 | Material agreement · Unregistered share sale · Other events ↗ |
| Jul 13, 2026 | Director or officer change ↗ |
| Jul 8, 2026 | Material agreement · Unregistered share sale · Other events ↗ |
| Jun 29, 2026 | Shareholder vote ↗ |
| May 6, 2026 | Results ↗ |
| Feb 23, 2026 | Results ↗ |
| Feb 18, 2026 | Director or officer change ↗ |
| Jan 12, 2026 | Regulation FD ↗ |
| Nov 4, 2025 | Results ↗ |